Vitae Pharmaceuticals Inc


Wedbush Downgrades Vitae Pharmaceuticals Inc (VTAE) Following Acquisition By Allergan

In a research report published Wednesday, Wedbush analyst Liana Moussatos downgraded shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) from Outperform to Neutral, while reducing the …

Mizuho Top Analyst Weighs in on Allergan plc Ordinary Shares (AGN) Amid Vitae Pharmaceuticals Inc (VTAE) Acquisition

Allergan plc Ordinary Shares (NYSE:AGN) announced today that it had entered an agreement to acquire Vitae Pharmaceuticals Inc (NASDAQ:VTAE), a clinical-stage biotech company, …

Stock Update (NASDAQ:VTAE): Here’s Why Vitae Pharmaceuticals Inc Shares Are Soaring 150%

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) and Allergan plc (NYSE:AGN) announced that they have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 …

Wedbush Raises Price Target for Vitae Pharmaceuticals Inc (VTAE) Following Positive Clinical Trial Results in Psoriasis

In a research note released Friday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE), while raising the …

Thursday Morning Market Insights: Vitae Pharmaceuticals Inc (VTAE), Bio Blast Pharma Ltd (ORPN), Ctrip.com International, Ltd. (ADR) (CTRP)

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) shares jumped 94% in pre-market trading after the company announced positive top-line results from its experimental psoriasis drug VTP-43742. The …

Company Update (NASDAQ:VTAE): Vitae Pharmaceuticals Inc Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis

Vitae Pharmaceuticals, Inc.(NASDAQ:VTAE), a clinical-stage biotechnology company, today announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts